About: Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections
Creator	Shapiro, Nathan Rosen, Jeffrey Filbin, Michael Hou, Peter Kurz, Michael Parekh, Amisha Self, Wesley Sharp, Stephan
source	Medline; PMC
abstract	C-reactive protein (CRP) and myxovirus resistance protein A (MxA) are associated with bacterial and viral infections, respectively. We conducted a prospective, multicenter, cross-sectional study of adults and children with febrile upper respiratory tract infections (URIs) to evaluate the diagnostic accuracy of a rapid CRP/MxA immunoassay to identify clinically significant bacterial infection with host response and acute pathogenic viral infection. The reference standard for classifying URI etiology was an algorithm that included throat bacterial culture, upper respiratory PCR for viral and atypical pathogens, procalcitonin, white blood cell count, and bandemia. The algorithm also allowed for physician override. Among 205 patients, 25 (12.2%) were classified as bacterial, 53 (25.9%) as viral, and 127 (62.0%) negative by the reference standard. For bacterial detection, agreement between FebriDx and the reference standard was 91.7%, with FebriDx having a sensitivity of 80% (95% CI: 59–93%), specificity of 93% (89–97%), positive predictive value (PPV) of 63% (45–79%), and a negative predictive value (NPV) of 97% (94–99%). For viral detection, agreement was 84%, with a sensitivity of 87% (75–95%), specificity of 83% (76–89%), PPV of 64% (63–75%), and NPV of 95% (90–98%). FebriDx may help to identify clinically significant immune responses associated with bacterial and viral URIs that are more likely to require clinical management or therapeutic intervention, and has potential to assist with antibiotic stewardship.
has issue date	2017-10-07(xsd:dateTime)
bibo:doi	10.3390/jcm6100094
bibo:pmid	28991170
has license	cc-by
sha1sum (hex)	b8e9c45dda9cb8c9c4321a55704ab2a66fb34f7d
schema:url	https://doi.org/10.3390/jcm6100094
resource representing a document's title	Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections
has PubMed Central identifier	PMC5664009
has PubMed identifier	28991170
schema:publication	J Clin Med
resource representing a document's body	covid:b8e9c45dda9cb8c9c4321a55704ab2a66fb34f7d#body_text
is schema:about of	named entity 'BACTERIAL' named entity 'ALGORITHM' named entity 'BACTERIAL INFECTION' named entity 'RESISTANCE' named entity 'DIAGNOSTIC ACCURACY' named entity 'IMMUNOASSAY' named entity 'UPPER' named entity 'UPPER RESPIRATORY TRACT INFECTIONS' named entity 'VIRAL AND' named entity 'ASSOCIATED WITH' named entity 'ANTIBIOTIC' named entity 'NPV' named entity 'PHYSICIAN' named entity 'ETIOLOGY' named entity 'SENSITIVITY' named entity 'CLASSIFIED' named entity 'PATHOGENIC' named entity 'PATHOGENS' named entity 'POTENTIAL' named entity 'VIRAL DETECTION' named entity 'RESPIRATORY' named entity 'ACUTE' named entity 'UPPER RESPIRATORY INFECTIONS' named entity 'WHITE BLOOD CELL COUNT' named entity 'TO DETECT' named entity 'CLINICAL MEDICINE' named entity 'VIRAL AND' named entity 'RAPID' named entity 'PROSPECTIVE' named entity 'ASSIST' named entity '2889' named entity 'CLINICAL MANAGEMENT' named entity 'LIKELY' named entity 'EVALUATE' named entity 'FEBRILE' named entity 'ATYPICAL' named entity 'VIRAL' named entity 'URI' named entity 'CLASSIFYING' named entity 'SIGNIFICANT' named entity 'THROAT' named entity 'HELP' named entity 'AGREEMENT' named entity 'HOST RESPONSE' named entity 'DIAGNOSTIC ACCURACY' named entity 'RAPID' named entity 'PPV' named entity 'CROSS-SECTIONAL STUDY' named entity 'BACTERIAL DETECTION' named entity 'NEGATIVE PREDICTIVE VALUE' named entity 'IMMUNE RESPONSES' named entity 'REFERENCE STANDARD' named entity 'STEWARDSHIP' named entity 'C-REACTIVE PROTEIN' named entity 'CHILDREN' named entity 'BACTERIAL' named entity 'ADULTS' named entity 'PATIENTS' named entity 'PROCALCITONIN' named entity 'INCLUDED' named entity 'MYXOVIRUS' named entity 'PROTEIN A' named entity 'THERAPEUTIC INTERVENTION' named entity 'OVERRIDE' named entity 'TEST' named entity 'NEGATIVE' named entity 'VIRAL INFECTION' named entity 'ALLOWED' named entity 'CRP' named entity 'URIS' named entity '80%' named entity 'POSITIVE PREDICTIVE VALUE' named entity 'TO IDENTIFY' named entity 'BANDEMIA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software